Andrew Jackson has served as interim CEO since August and will remain as the company’s chief financial officer.
“Will’s extensive industry experience, particularly in the vascular space, makes him an ideal fit to lead Ra Medical,” chairman Martin Colombatto said in a news release. “He’s built an impressive career at industry-leading medical device companies introducing new products, scaling commercial organizations, developing and implementing corporate strategies, exceeding sales projections and building high performing corporate cultures. His experience, energy and focus will help guide our product development, regulatory and commercial plans for DABRA, while we improve product reliability, expand our product offerings and enhance the experience for physicians and patients. We welcome Will to our executive team and to our board.”
McGuire most recently served as president and CEO of Second Sight Medical and will remain on its board as a director. Prior to Second Sight, he held numerous leadership positions at Volcano Corporation, Covidien, Spectranetics, Guidant and IVAC Medical Systems.
“I am excited for the opportunity to lead the talented team at Ra Medical. I believe the commercial opportunity for the Company is especially compelling given the advantages of DABRA photoablation for the treatment of peripheral artery disease,” McGuire said. “DABRA quickly dissolves plaque with minimal vascular trauma in a disease that affects over 17 million people in the U.S. alone. I look forward to working with my new colleagues to advance the commercialization of DABRA and drive the adoption of this game-changing technology.”